The Bio International Convention partnering conference was held June 3-6 in San Diego, California. Sprint Biosciences CEO Johan Emilsson was present.

What general impressions will you take home from the conference?
This conference is almost always very busy. It is one of the largest and most prestigious partnering conferences in biotechnology and drug development with thousands of participants from all over the world. It brings together investors, researchers, industry leaders and potential partners, all with a strong desire to discover the latest innovations and technologies in biotechnology. The high concentration of industry players creates a dynamic and exciting environment to discuss future medical solutions.

And how much interest was there in Sprint Bioscience?
Big. With the positive development we have in our programs, we see an increased interest in meeting with us and discussing the potential our programs provide. Even at an early stage before the conference started, we had many booked meetings with interested companies.

What have been your main objectives for the conference?
Above all, we were there to present our latest research results to potential partners, while making new contacts and deepening existing relationships. In addition, we see the conference as an important forum to keep up to date with the latest trends and innovations in the biotechnology sector.

When promoting your programs, what makes Sprint Bioscience unique?
We stand out because we are very quick to identify and develop new therapeutic opportunities in areas of high unmet medical need. We focus on innovative, small molecule drugs and have an efficient drug development platform. We have an experienced scientific team and collaborate with leading academic institutions to maximize our success. Our unique combination of technical expertise and early out-licensing makes us an attractive player in the sector.

What is the future after the conference?
We look forward to building on the contacts and opportunities developed during the conference. We continue our efforts to deliver high-quality research results and to pave the way for our programs towards clinical development. We are very optimistic about the future.